AstraZeneca in drive to slash costs Hostile environment prompts root and branch review. Exanta unlikely to win US approval in near future. By Stephen Foley. AstraZeneca, the UK #39;s number two pharmaceuticals company, has launched a  quot;root and branch  
Is this a piece of news regarding world politics, sports, business, or science and technology? 